PMID- 33571038
OWN - NLM
STAT- MEDLINE
DCOM- 20220516
LR  - 20220531
IS  - 1557-8852 (Electronic)
IS  - 1084-9785 (Linking)
VI  - 37
IP  - 4
DP  - 2022 May
TI  - E2F1-Induced FTH1P3 Promoted Cell Viability and Glycolysis Through 
      miR-377-3p/LDHA Axis in Laryngeal Squamous Cell Carcinoma.
PG  - 276-286
LID - 10.1089/cbr.2020.4266 [doi]
AB  - Background: Laryngeal squamous cell carcinoma (LSCC) has poor prognosis, and the 
      mechanism underlying the pathogenesis of LSCC remains unclear. Recently, a study 
      has shown that long nonprotein coding RNA ferritin heavy chain 1 pseudogene 3 
      (FTH1P3) plays a crucial role in tumor pathogenesis. This study explored the 
      potential role of FTH1P3 in LSCC. Materials and Methods: The expression of E2F1 
      and FTH1P3 in LSCC was analyzed by quantitative real time-polymerase chain 
      reaction assay. The direct targets of FTH1P3 and miR-377-3p were predicted, 
      followed by functional validation. The functional role of FTH1P3 was investigated 
      in AMC-HN-8 and TU686 cells using 
      3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays and the 
      measurement of glucose uptake and L-lactate production. Results: The results 
      showed that overexpression of FTH1P3 promoted cell viability and glycolysis in 
      LSCC cells, but knockdown of FTH1P3 suppressed this behavior. Upregulated FTH1P3 
      was associated with increased E2F1 expression in LSCC patients. E2F1 was proved 
      to induce FTH1P3 expression in LSCC cells. FTH1P3 modulated miR-377-3p expression 
      by targeting miR-377-3p. Interestingly, LDHA was identified to be a target of 
      miR-377-3p, and FTH1P3 promoted LDHA expression by suppressing miR-377-3p. In 
      addition, knockdown of FTH1P3 mitigated E2F1-induced cell viability and 
      glycolysis through miR-377-3p/LDHA in AMC-HN-8 cells. More importantly, knockdown 
      of E2F1 inhibited tumor growth and FTH1P3 expression in vivo. Conclusion: In 
      conclusion, these findings revealed that E2F1-induced FTH1P3 promoted cell 
      viability and glycolysis through miR-377-3p/LDHA axis in LSCC, which could 
      provide a promising novel strategy for LSCC treatment.
FAU - Zhao, Lina
AU  - Zhao L
AD  - Department of Otolaryngology-Head and Neck Surgery, Sir Run Run Shaw Hospital, 
      Medical College of Zhejiang University, Hangzhou City, China.
FAU - Zheng, Yi
AU  - Zheng Y
AD  - Department of Otolaryngology, Zhejiang Provincial People's Hospital, People's 
      Hospital of Hangzhou Medical College, Hangzhou City, China.
FAU - Zhang, Lei
AU  - Zhang L
AD  - Department of Otolaryngology-Head and Neck Surgery, Sir Run Run Shaw Hospital, 
      Medical College of Zhejiang University, Hangzhou City, China.
FAU - Su, Lizhong
AU  - Su L
AD  - Department of Otolaryngology, Zhejiang Provincial People's Hospital, People's 
      Hospital of Hangzhou Medical College, Hangzhou City, China.
LA  - eng
PT  - Journal Article
DEP - 20210210
PL  - United States
TA  - Cancer Biother Radiopharm
JT  - Cancer biotherapy & radiopharmaceuticals
JID - 9605408
RN  - 0 (E2F1 Transcription Factor)
RN  - 0 (E2F1 protein, human)
RN  - 0 (MIRN377 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (long non coding RNA FTH1P3, human)
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
RN  - EC 1.1.1.27 (LDHA protein, human)
SB  - IM
MH  - Cell Line, Tumor
MH  - Cell Proliferation/genetics
MH  - Cell Survival
MH  - *E2F1 Transcription Factor/genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - Glycolysis
MH  - Humans
MH  - *L-Lactate Dehydrogenase/genetics
MH  - *Laryngeal Neoplasms/genetics/pathology
MH  - *MicroRNAs/genetics
MH  - *RNA, Long Noncoding/genetics
MH  - *Squamous Cell Carcinoma of Head and Neck/genetics/pathology
OTO - NOTNLM
OT  - E2F1
OT  - FTH1P3
OT  - LDHA
OT  - glycolysis
OT  - laryngeal squamous cell carcinoma
OT  - miR-377-3p
EDAT- 2021/02/12 06:00
MHDA- 2022/05/17 06:00
CRDT- 2021/02/11 17:12
PHST- 2021/02/12 06:00 [pubmed]
PHST- 2022/05/17 06:00 [medline]
PHST- 2021/02/11 17:12 [entrez]
AID - 10.1089/cbr.2020.4266 [doi]
PST - ppublish
SO  - Cancer Biother Radiopharm. 2022 May;37(4):276-286. doi: 10.1089/cbr.2020.4266. 
      Epub 2021 Feb 10.